Pamaquine

From Wikipedia, the free encyclopedia

Pamaquine
Systematic (IUPAC) name
N,N-diethyl-N'-(6-methoxyquinolin-8-yl)pentane-
1,4-diamine
Identifiers
CAS number 491-92-9
ATC code  ?
PubChem 10290
Chemical data
Formula C19H29N3O 
Mol. mass 315.453 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Pamaquine is an 8-aminoquinoline drug used for the treatment of malaria. It is closely related to primaquine.

Contents

[edit] History

Pamaquine was the first synthetic antimalarial drug.

[edit] Adverse effects

Like primaquine, pamaquine causes haemolytic anaemia in patients with G6PD deficiency. Patients should therefore always be screened for G6PD deficiency prior to being prescribed pamaquine.

[edit] Uses

Pamaquine is effective against the hypnozoites of the relapsing malarias (P. vivax and P. ovale); and unlike primaquine, it is also very effective against the erythrocytic stages of all four human malarias. One small clinical trial of pamaquine as a causal prophylactic was disappointing[1] (whereas primaquine is an extremely effective causal prophylactic).

[edit] Dosing

60 mg once daily for 14–21 days.

When treating Plasmodium vivax, an initial course of chloroquine is unnecessary.

[edit] Synonyms

  • Plasmaquine

[edit] References

  1. ^ Sweeney AW, Blackburn CRB, KH Rieckmann. (2004). "Short report: The activity of pamaquine, an 8-aminoquinoline drug, against sporozoite-induced infections of Plasmodium vivax (New Guinea strains)". Am J Trop Med Hyg 71 (2): 187-189.